Connect Biopharma to Present at Leerink Healthcare Conference — Connect Biopharma Holdings Limited

Event summary

Connect Biopharma will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on March 10, 2026, at 8:00 a.m. ET.
The presentation will be webcast live and archived for 90 days on the company's investor relations website.
Connect Biopharma is focused on treating inflammatory diseases, particularly asthma and COPD, with its lead candidate rademikibart.
The company has an exclusive license agreement with Simcere Pharmaceutical for rademikibart in Greater China, with potential milestone payments up to $110 million and tiered royalties.

The big picture

Connect Biopharma's participation in the Leerink Partners Global Healthcare Conference underscores its strategic focus on advancing its lead candidate, rademikibart, for inflammatory diseases. The company's partnership with Simcere Pharmaceutical highlights its efforts to expand into the lucrative Greater China market, where significant unmet needs in asthma and COPD treatment exist. The potential milestone payments and royalties from this agreement could provide substantial financial benefits, but the company's success will depend on the progress of its clinical trials and market execution.

What we're watching

Clinical Progress: The pace at which Connect Biopharma advances its global clinical studies for rademikibart in treating asthma and COPD exacerbations.
Market Expansion: Whether the company can leverage its partnership with Simcere Pharmaceutical to successfully penetrate the Greater China market.
Financial Performance: How the potential milestone payments and royalties from the Simcere agreement will impact Connect Biopharma's financial outlook.